miR-638 Upregulation in Serum and Tissues Functions as a Diagnostic and Prognostic Biomarker and Facilitates Prostate Cancer Progression
Abstract
OBJECTIVE
To explore the expression profile of miR-638 in serum and tumor tissues of prostate cancer (CaP) individuals, and further analyze its diagnostic value, prognostic significance, and regulatory role in CaP cells.
METHODS
Serum was collected from individuals with CaP, benign prostatic hyperplasia (BPH), and healthy controls (HC). Paired tumor and adjacent normal tissues were obtained from CaP cases. miR-638 expression was determined by qRT-PCR. ROC curve was performed to evaluate the diagnostic efficacy of serum miR-638 alone and in combination with t-PSA. Spearman's rank was used to analyze the association between tissue miR-638 and clinicopathological features. Kaplan-Meier and multivariate Cox regression were used to identify prognostic factors. In vitro, CCK‑8, flow cytometry, and Transwell assays were performed to evaluate PC‑3 cell proliferation, apoptosis, migration, and invasion.
RESULTS
miR-638 was significantly upregulated in the serum of CaP individuals compared with BPH and HC, presenting a stepwise upregulation trend. Combined detection of serum miR-638 and t-PSA significantly improved the diagnostic performance for CaP. High miR-638 expression in tumor tissues was closely associated with adverse clinicopathological parameters and predicted shorter overall survival. Multivariate Cox regression demonstrated that tissue miR-638 overexpression was an independent poor prognostic factor. In vitro assays demonstrated that miR-638 overexpression promoted the…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.